MA37400A1 - Composés hétérocyclyle en tant qu'inhibiteurs de mek - Google Patents

Composés hétérocyclyle en tant qu'inhibiteurs de mek

Info

Publication number
MA37400A1
MA37400A1 MA37400A MA37400A MA37400A1 MA 37400 A1 MA37400 A1 MA 37400A1 MA 37400 A MA37400 A MA 37400A MA 37400 A MA37400 A MA 37400A MA 37400 A1 MA37400 A1 MA 37400A1
Authority
MA
Morocco
Prior art keywords
compounds
cyclil
heterogeneous
mek inhibitors
present disclosure
Prior art date
Application number
MA37400A
Other languages
Arabic (ar)
English (en)
Other versions
MA37400B1 (fr
Inventor
Bhavesh Dave
Rakesh Kumar Banerjee
Samiron Phukan
Abhijit Datta Khoje
Rajkumar Hangarge
Jitendra Sambhaji Jadhav
Venkata P Palle
Rajender Kumar Kamboj
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47997632&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA37400(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of MA37400A1 publication Critical patent/MA37400A1/fr
Publication of MA37400B1 publication Critical patent/MA37400B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)

Abstract

La présente invention concerne des composés hétéroaryle en tant qu'inhibiteurs de mek. Ces composés comprennent des composés hétéroaryle de formule (i), leurs sels pharmaceutiquement acceptables, des combinaisons avec un médicament approprié et des compositions pharmaceutiques de ceux-ci. La présente invention concerne également des procédés de préparation des composés et leur utilisation dans des méthodes de traitement. Les composés selon la présente invention sont représentés par la formule (i).
MA37400A 2012-03-14 2013-03-11 Composés hétérocyclyle en tant qu'inhibiteurs de mek MA37400B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN288KO2012 2012-03-14
PCT/IB2013/051908 WO2013136249A1 (fr) 2012-03-14 2013-03-11 Composés hétérocyclyle en tant qu'inhibiteurs de mek

Publications (2)

Publication Number Publication Date
MA37400A1 true MA37400A1 (fr) 2016-05-31
MA37400B1 MA37400B1 (fr) 2019-11-29

Family

ID=47997632

Family Applications (2)

Application Number Title Priority Date Filing Date
MA37405A MA37405A1 (fr) 2012-03-14 2013-03-11 Composés hétérocyclyle
MA37400A MA37400B1 (fr) 2012-03-14 2013-03-11 Composés hétérocyclyle en tant qu'inhibiteurs de mek

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA37405A MA37405A1 (fr) 2012-03-14 2013-03-11 Composés hétérocyclyle

Country Status (35)

Country Link
US (5) US9428499B2 (fr)
EP (2) EP2834237B1 (fr)
JP (3) JP6093384B2 (fr)
KR (4) KR20140138911A (fr)
CN (4) CN107698585A (fr)
AP (2) AP3834A (fr)
AU (4) AU2013234014B2 (fr)
BR (1) BR112014022713B1 (fr)
CA (2) CA2865167C (fr)
CL (2) CL2014002412A1 (fr)
CO (2) CO7160029A2 (fr)
CR (2) CR20140464A (fr)
CU (2) CU24335B1 (fr)
DK (2) DK2834236T3 (fr)
DO (2) DOP2014000204A (fr)
EA (2) EA029768B1 (fr)
ES (2) ES2741896T3 (fr)
GE (2) GEP201706774B (fr)
GT (2) GT201400196A (fr)
IL (2) IL234559A (fr)
IN (2) IN2014MN01754A (fr)
MA (2) MA37405A1 (fr)
MX (3) MX355526B (fr)
MY (2) MY174188A (fr)
NI (2) NI201400107A (fr)
NZ (2) NZ629432A (fr)
PE (2) PE20141973A1 (fr)
PH (2) PH12014502040B1 (fr)
PL (1) PL2834237T3 (fr)
SG (2) SG11201405007QA (fr)
TN (2) TN2014000357A1 (fr)
TR (1) TR201811976T4 (fr)
UA (2) UA114906C2 (fr)
WO (2) WO2013136249A1 (fr)
ZA (1) ZA201406186B (fr)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012088266A2 (fr) 2010-12-22 2012-06-28 Incyte Corporation Imidazopyridazines et benzimidazoles substitués en tant qu'inhibiteurs de fgfr3
UA114906C2 (uk) 2012-03-14 2017-08-28 Люпін Лімітед Гетероциклільні сполуки як інгібітори мек
US9611267B2 (en) 2012-06-13 2017-04-04 Incyte Holdings Corporation Substituted tricyclic compounds as FGFR inhibitors
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
TWI649318B (zh) 2013-04-19 2019-02-01 英塞特控股公司 作為ｆｇｆｒ抑制劑之雙環雜環
US9914703B2 (en) * 2013-10-25 2018-03-13 Shanghai Hengrui Pharmaceutical Co., Ltd. Pyridic ketone derivatives, method of preparing same, and pharmaceutical application thereof
WO2016009306A1 (fr) * 2014-07-15 2016-01-21 Lupin Limited Composés hétérocyclyles utilisés comme inhibiteurs de mek
WO2016035008A1 (fr) * 2014-09-04 2016-03-10 Lupin Limited Dérivés de pyridopyrimidine utilisés comme inhibiteurs de mek
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
WO2016134294A1 (fr) 2015-02-20 2016-08-25 Incyte Corporation Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
AU2016219822B2 (en) 2015-02-20 2020-07-09 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
EP3558979B1 (fr) 2016-12-22 2021-02-17 Boehringer Ingelheim International GmbH Nouvelles quinazolines substituées benzylamino et dérivés en tant qu'inhibiteurs de sos1
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
TWI870922B (zh) 2017-12-21 2025-01-21 德商百靈佳殷格翰國際股份有限公司 作為sos1抑制劑之新穎芐胺基取代吡啶并嘧啶酮及衍生物
TW201946630A (zh) 2018-05-04 2019-12-16 美商英塞特公司 Fgfr抑制劑之鹽
ES2991427T3 (es) 2018-05-04 2024-12-03 Incyte Corp Formas sólidas de un inhibidor de FGFR y procedimientos para preparar las mismas
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
BR112021018168B1 (pt) 2019-03-21 2023-11-28 Onxeo Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
CN114375202A (zh) 2019-06-19 2022-04-19 勃林格殷格翰国际有限公司 抗癌组合疗法
WO2021007269A1 (fr) 2019-07-09 2021-01-14 Incyte Corporation Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
MX2022001328A (es) * 2019-07-30 2022-05-20 Edvince Ab Inhibidor de proteina quinasa quinasa activada por mitogeno (mek) para el tratamiento de apoplejia.
EP3797899A1 (fr) 2019-09-27 2021-03-31 Primetals Technologies Austria GmbH Dispositif et procédé de détection d'un mouvement d'un corps dans une installation industrielle
WO2021067374A1 (fr) 2019-10-01 2021-04-08 Incyte Corporation Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
GEAP202415945A (en) 2019-10-14 2024-04-25 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (fr) 2019-10-16 2021-04-22 Incyte Corporation Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
CA3159348A1 (fr) 2019-11-08 2021-05-14 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methodes pour le traitement de cancers qui ont acquis une resistance aux inhibiteurs de kinase
AU2020395185A1 (en) 2019-12-04 2022-06-02 Incyte Corporation Derivatives of an FGFR inhibitor
CA3163875A1 (fr) 2019-12-04 2021-06-10 Incyte Corporation Heterocycles tricycliques en tant qu'inhibiteurs de fgfr
WO2021146424A1 (fr) 2020-01-15 2021-07-22 Incyte Corporation Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation
BR112022023462A2 (pt) 2020-06-02 2022-12-20 Boehringer Ingelheim Int 2-amino-3-ciano tiofenos anulados e derivados para o tratamento de câncer
TWI825637B (zh) 2021-03-31 2023-12-11 美商輝瑞股份有限公司 啶－１，６（２ｈ，７ｈ）－二酮
WO2022214594A1 (fr) 2021-04-09 2022-10-13 Boehringer Ingelheim International Gmbh Thérapie anticancéreuse
EP4323405A1 (fr) 2021-04-12 2024-02-21 Incyte Corporation Polythérapie comprenant un inhibiteur de fgfr et un agent de ciblage de nectine-4
KR20230172548A (ko) * 2021-04-16 2023-12-22 이케나 온콜로지, 인코포레이티드 Mek 억제제 및 이의 용도
US12280055B2 (en) 2021-05-27 2025-04-22 Mirati Therapeutics, Inc. Combination therapies
CA3220274A1 (fr) 2021-06-09 2022-12-15 Incyte Corporation Heterocycles tricycliques en tant qu'inhibiteurs de fgfr
AR126101A1 (es) 2021-06-09 2023-09-13 Incyte Corp Heterociclos tricíclicos como inhibidores de fgfr
CN119841847A (zh) 2021-12-01 2025-04-18 勃林格殷格翰国际有限公司 用于治疗癌症的环状2-氨基-3-氰基噻吩及其衍生物
JP2024543976A (ja) 2021-12-01 2024-11-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌の処置のための環化２－アミノ－３－シアノチオフェン及び誘導体
CN118591540A (zh) 2021-12-01 2024-09-03 勃林格殷格翰国际有限公司 包含环状2-氨基-3-氰基噻吩的kras降解化合物
US20250129096A1 (en) 2021-12-01 2025-04-24 Boehringer Ingelheim Int'l GmbH Corp. Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
US20250129095A1 (en) 2021-12-01 2025-04-24 Boehringer Ingelheim Int'l GmbH Corp. Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
CN114573581B (zh) * 2022-03-30 2023-09-01 沈阳药科大学 5-取代氨基-1,3-二取代苯基吡啶并[2,3-d]嘧啶类化合物及其制备与应用
CN114605408B (zh) * 2022-03-30 2023-06-16 沈阳药科大学 5-羟基-1,3-二取代苯基吡啶并[2,3-d]嘧啶类化合物及其制法和应用
CN114573582B (zh) * 2022-03-30 2023-06-16 沈阳药科大学 1,2,3,4-四氢吡啶并[2,3-d]嘧啶类化合物及其制备方法和应用
CN114456166B (zh) * 2022-03-30 2023-06-16 沈阳药科大学 5-取代氨基-3-甲基吡啶并[2,3-d]嘧啶类化合物及其制备与应用
TW202404581A (zh) 2022-05-25 2024-02-01 美商醫肯納腫瘤學公司 Ｍｅｋ抑制劑及其用途
JP2024047569A (ja) * 2022-09-26 2024-04-05 ファイザー・インク Ｍｅｋ阻害剤としての３，４－ジヒドロ－２，７－ナフチリジン－１，６（２ｈ，７ｈ）－ジオン
AR132802A1 (es) 2023-05-30 2025-07-30 Boehringer Ingelheim Int 2-amino-3-cianotiofenos con anillos espirocíclicos y derivados para el tratamiento del cáncer
WO2025073765A1 (fr) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Méthodes de pronostic et de traitement de patients souffrant de mélanome

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
UA72612C2 (en) * 2000-07-06 2005-03-15 Pyrido[2.3-d]pyrimidine and pyrimido[4.5-d]pyrimidine nucleoside analogues, prodrugs and method for inhibiting growth of neoplastic cells
US6825180B2 (en) * 2001-05-18 2004-11-30 Cell Therapeutics, Inc. Pyridopyrimidine compounds and their uses
GB0129099D0 (en) 2001-12-05 2002-01-23 Astrazeneca Ab Chemical compounds
DE60303009T2 (de) * 2002-01-22 2006-07-13 Warner-Lambert Co. Llc 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-one
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
CN1905873A (zh) 2003-11-19 2007-01-31 阵列生物制药公司 Mek的杂环抑制剂及其使用方法
US7378423B2 (en) 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
JP4163738B2 (ja) * 2004-06-11 2008-10-08 日本たばこ産業株式会社 癌の治療用の５−アミノ−２，４，７−トリオキソ−３，４，７，８−テトラヒドロ−２Ｈ−ピリド’２，３−ｄ！ピリミジン誘導体及び関連化合物
AU2009344690A1 (en) 2009-04-21 2011-10-27 Novartis Ag Heterocyclic compounds as MEK inhibitors
UA114906C2 (uk) * 2012-03-14 2017-08-28 Люпін Лімітед Гетероциклільні сполуки як інгібітори мек

Also Published As

Publication number Publication date
MX355526B (es) 2018-04-20
DK2834236T3 (da) 2019-08-26
EP2834236A1 (fr) 2015-02-11
AP2014008009A0 (en) 2014-10-31
CR20140464A (es) 2014-11-28
PH12014502041B1 (en) 2014-11-24
MA37400B1 (fr) 2019-11-29
CU20140109A7 (es) 2014-11-27
US9555035B2 (en) 2017-01-31
JP6630771B2 (ja) 2020-01-15
HK1206020A1 (en) 2015-12-31
US9573944B2 (en) 2017-02-21
NI201400108A (es) 2014-11-28
GT201400195A (es) 2017-11-09
US9969731B2 (en) 2018-05-15
IL234560A (en) 2017-06-29
BR112014022713A2 (fr) 2017-06-20
PE20141973A1 (es) 2014-12-12
NZ629442A (en) 2016-12-23
ZA201406186B (en) 2016-06-29
CU24335B1 (es) 2018-04-03
CN104271577A (zh) 2015-01-07
AU2013234014B2 (en) 2017-02-02
KR20190100472A (ko) 2019-08-28
MY174188A (en) 2020-03-12
AP3859A (en) 2016-10-31
JP6431770B2 (ja) 2018-11-28
CL2014002412A1 (es) 2015-03-06
CL2014002411A1 (es) 2015-04-06
MY175950A (en) 2020-07-16
TN2014000356A1 (en) 2015-12-21
US9827247B2 (en) 2017-11-28
GEP201706671B (en) 2017-05-25
MX2014010925A (es) 2015-04-10
CA2865164A1 (fr) 2013-09-19
PH12014502041A1 (en) 2014-11-24
UA114906C2 (uk) 2017-08-28
DOP2014000203A (es) 2015-02-15
CO7160029A2 (es) 2015-01-15
AU2013234009B2 (en) 2016-10-27
CO7170131A2 (es) 2015-01-28
ES2741896T3 (es) 2020-02-12
PH12014502040A1 (en) 2014-11-24
KR20140138911A (ko) 2014-12-04
AP3834A (en) 2016-09-30
MX355474B (es) 2018-04-16
CA2865167A1 (fr) 2013-09-19
MX366426B (es) 2019-07-08
US20170112840A1 (en) 2017-04-27
WO2013136254A1 (fr) 2013-09-19
UA114907C2 (uk) 2017-08-28
AU2018202568B2 (en) 2019-05-09
PE20141974A1 (es) 2014-12-12
CA2865167C (fr) 2019-08-06
US20170101408A1 (en) 2017-04-13
EA028232B1 (ru) 2017-10-31
JP2015514056A (ja) 2015-05-18
CN104203947A (zh) 2014-12-10
ES2684517T3 (es) 2018-10-03
AU2017200493A1 (en) 2017-02-16
EP2834236B1 (fr) 2019-05-22
DOP2014000204A (es) 2015-02-15
NZ629432A (en) 2017-01-27
CN108383836A (zh) 2018-08-10
KR20140138910A (ko) 2014-12-04
AU2018202568A1 (en) 2018-05-10
US20150299186A1 (en) 2015-10-22
SG11201405007QA (en) 2014-10-30
AU2013234009A1 (en) 2014-09-25
CN108383836B (zh) 2021-11-12
AP2014008008A0 (en) 2014-10-31
US20160331753A1 (en) 2016-11-17
NI201400107A (es) 2014-11-26
KR20190073597A (ko) 2019-06-26
PH12014502040B1 (en) 2014-11-24
EA201491672A1 (ru) 2014-12-30
EP2834237A1 (fr) 2015-02-11
JP2018115215A (ja) 2018-07-26
GEP201706774B (en) 2017-11-27
EA201491671A1 (ru) 2014-12-30
US20150133424A1 (en) 2015-05-14
MX2014010928A (es) 2015-04-10
CU24272B1 (es) 2017-08-08
EP2834237B1 (fr) 2018-06-06
AU2017200493B2 (en) 2018-03-29
JP6093384B2 (ja) 2017-03-08
CR20140463A (es) 2014-11-28
HK1202538A1 (en) 2015-10-02
KR102240101B1 (ko) 2021-04-14
CA2865164C (fr) 2021-06-08
US9428499B2 (en) 2016-08-30
AU2013234014A1 (en) 2014-09-25
EA029768B1 (ru) 2018-05-31
MA37405A1 (fr) 2016-03-31
DK2834237T3 (en) 2018-08-27
IN2014MN01754A (fr) 2015-07-03
JP2015509975A (ja) 2015-04-02
TR201811976T4 (tr) 2018-09-21
WO2013136249A1 (fr) 2013-09-19
CN107698585A (zh) 2018-02-16
PL2834237T3 (pl) 2018-11-30
IL234559A (en) 2017-06-29
GT201400196A (es) 2017-09-28
IN2014MN01755A (fr) 2015-07-03
KR102241111B1 (ko) 2021-04-15
SG11201405006PA (en) 2014-10-30
BR112014022713B1 (pt) 2021-09-08
CU20140110A7 (es) 2014-11-27
TN2014000357A1 (en) 2015-12-21

Similar Documents

Publication Publication Date Title
MA37400A1 (fr) Composés hétérocyclyle en tant qu'inhibiteurs de mek
IN2014DN09434A (fr)
EA201690287A1 (ru) 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом
IN2015DN01156A (fr)
MX365939B (es) Moduladores del transporte nuclear y usos de los mismos.
MD20140063A2 (ro) Derivaţi de acid benzotiazol-6-il acetic şi utilizarea acestora pentru tratarea unei infecţii HIV
MX345928B (es) Composiciones terapeuticamente activas y metodos de uso de las mismas.
EA201790661A2 (ru) Ингибиторы вируса гепатита c
EA201690223A1 (ru) Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение
EA201490228A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
IN2014MN02652A (fr)
MX341565B (es) 3-amino-piridinas como agonistas de receptor de acido biliar acoplado a proteina g1 (gpbar1).
EA201591195A1 (ru) Новые хинолоновые производные
EA201490103A1 (ru) Гидроксиметиларилзамещенные пирролотриазины в качестве ингибиторов alk1
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
MD20170011A2 (ro) Compuşi imidazopiridazinici
MX2014014308A (es) Pirrolidino heterociclos.
EA201491227A1 (ru) Новые производные морфолинила, подходящие для применения в качестве ингибиторов mogat-2
MX2013002208A (es) Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes.
PH12015500399A1 (en) Azaindolines
MD20160111A2 (ro) Derivaţi diheterociclici legaţi de cicloalchil
EA201491878A1 (ru) Замещенные ксантиновые производные
MX2014005538A (es) 1-piridazinil-hidroxiimino-3-fenil-propanos como agonistas de proteina g-receptor acoplado a acido biliar 1 (gpbar1).
MX2013011561A (es) Compuestos de benzodioxepina y benzodioxina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes.
CA2863110A1 (fr) Derives de 1,2-pyridazine, 1,6-pyridazine ou pyrimidine-benzamide comme modulateurs de gpbar1